Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria1, Sangeetha M. Reddy2, Hussein A. Tawbi1, Michael A. Davies1, Merrick I. Ross3, Isabella C. Glitza1, Janice N. Cormier3, Carol Lewis4, Wen-Jen Hwu1, Ehab Hanna4, Adi Diab1, Michael K. Wong1, Richard Royal3, Neil Gross4, Randal Weber4, Stephen Y. Lai4, Richard Ehlers3, Jorge Blando5, Denái R. Milton6, Scott Woodman1, Robin Kageyama7, Danny K. Wells7, Patrick Hwu1, Sapna P. Patel1, Anthony Lucci3, Amy Hessel4, Jeffrey E. Lee3, Jeffrey Gershenwald3, Lauren Simpson1, Elizabeth M. Burton3, Liberty Posada1, Lauren Haydu3, Linghua Wang8, Shaojun Zhang8, Alexander J. Lazar 9, Courtney W. Hudgens 9, Vancheswaran Gopalakrishnan3, Alexandre Reuben3, Miles C. Andrews3, Christine N. Spencer8, Victor Prieto9, Padmanee Sharma5,10, James Allison5, Michael T. Tetzlaff9,11 and Jennifer A. Wargo3,8 1Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 2Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 3Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 4Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA. 5Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA. 6Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA. 7Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 8Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. 9Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA. 10Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA. 11Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.